Two Year - Real-World Outcomes Of Miniject Supraciliary Minimally Invasive Glaucoma Surgery In Australia
Published 2026 - 44th Congress of the ESCRS
Reference: FP04.12 | Type: Free paper | DOI: 10.82333/y27j-1v49
Authors: Dr Andrew White* 1 , Dr Leo Fan 1 , Dr Geoff Ryan 2 , Dr Nathan Kerr 3 , Dr Simon Phipps 4 , Dr Jason Cheng 5 , A/Prof. Ashish Agar 6 , Dr Chih-Hung Kuo 7
1Department of Ophthalmology,Westmead Hospital, ,Westmead,Australia, 2The Queensland Eye Institute Foundation,Wooloongabba,Australia, 3Eye Surgery Associates,Melbourne,Australia, 4Goodwood Eye Centre,Adelaide,Australia, 5Sydney Eye Hospital,Sydney,Australia, 6Marsden Eye Specialists,Parramatta,Australia, 7Capital Ophthalmology,Canberra,Australia
Purpose
To evaluate the real-world effectiveness and safety of the MINIject supraciliary minimally invasive glaucoma implant in an Australian multicentre cohort.
Setting
Retrospective multicentre case series from 8 Australian centres involving patients undergoing MINIject implantation, either as a standalone procedure or combined with phacoemulsification.
Methods
Data from 212 eyes of 176 patients who underwent MINIject implantation, with or without phacoemulsification, were analysed. Primary outcomes were intraocular pressure (IOP) and medication burden at last review. Secondary outcomes included surgical success, defined as IOP reduction of at least 20% from baseline, IOP between 6-21 mmHg, and no further glaucoma operation. Additional outcomes included monthly postoperative IOP, medication burden, visual acuity, adverse events, and reoperations.
Results
A total of 212 eyes from 176 patients were included. Mean age was 69.7 ± 18.4 years and 50% were female. Combined phacoemulsification was performed in 134/212 eyes (63.2%), 148/212 eyes (69.8%) had primary open-angle glaucoma, and 91/212 eyes (42.9%) were surgery-naive. Mean baseline IOP was 19.2 ± 7.5 mmHg and baseline medication burden was 2.5 ± 1.4. At last review, mean IOP reduced to 12.9 ± 5.3 mmHg and medication burden to 1.0 ± 1.3 (both p<0.05). Visual acuity remained stable (69.7 to 70.4, p=0.4). Hyphaema was the most common complication, followed by device malposition. Thirty eyes underwent further surgery, most commonly device revision.
Conclusions
In this real-world Australian multicentre series, MINIject was associated with significant reductions in IOP and medication burden, with stable visual acuity at last review. Device malposition and revision were notable postoperative issues. The frequency of revision may reflect a learning curve associated with early adoption of this newer supraciliary implant.